China Green Agriculture (NYSE: CGA) 30.4% HIGHER; reported Q2 EPS of $0.16, versus $0.12 reported last year.
Regulus Therapeutics Inc. (NASDAQ: RGLS) 16% LOWER; announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”). Treatment with a single subcutaneous dose of 4 mg/kg of RG-101 as monotherapy resulted in significant and sustained viral load reductions in all patients, including difficult to treat genotypes, various liver fibrosis status and those who